The following list of cancer immunotherapies are available for licensing under U.S. Patent Publication No.: 20220267730.

Ex Vivo Generation of Immunocytes Recognizing Brother of the Regulator of Imprinted Sites (BORIS) Expressing Cancer Stem Cells

Abstract
Disclosed are means, methods and compositions of matter useful for induction of immunity towards cancer stem cells by providing a dendritic cell, wherein said dendritic cells express BORIS and/or peptides derived from BORIS, wherein said dendritic cell is cultured in the presence of one or more immunocytes. In one embodiment said dendritic cells are derived from umbilical cord blood sources and allogeneic to T cells, which are expanded ex vivo and used for the purposes of immunotherapy.






Melanoma is a dangerous type of skin cancer that develops from melanocytes, the cells that produce melanin, the pigment that gives skin and hair their color.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Juvenile melanoma, also known as melanoma in children, is a rare but common skin cancer in children.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Lentigo maligna melanoma is a type of skin cancer that develops from a lentigo maligna, a precancerous condition.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Malignant melanoma, also known as melanoma, is a dangerous type of skin cancer that can develop from melanocytes, the cells that produce melanin and give skin its color.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Acral-lentiginous melanoma is a specific type of melanoma that appears on the palms of the hands, the soles of the feet, or under the nails.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Amelanotic melanoma, these skin lesions lack melanin, the dark pigment that gives most moles and melanomas their color. Instead, amelanotic melanomas can be clear, white or skin-colored, sometimes with a slight pink, purple or red tint.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Benign juvenile melanoma is an old term for a rare, noncancerous mole called a Spitz nevus.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Nodular melanoma subungal melanoma is a rare and aggressive form of skin cancer that can appear as a nodule under the nail.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Superficial spreading melanoma is a type of skin cancer that is the most common form of melanoma, accounting for 70–80% of cases.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%